T. Geiser (Bern, Switzerland), C. Kaehler (Innsbruck, Austria)
Wnt-inducible protein (WISP-1) is a key regulator of alveolar epithelial cell hyperplasia in pulmonary fibrosis
M. Koenigshoff, J. Wilhelm, A. Jahn, O. Amarie, K. Kitowska, A. Wilhelm, R. M. Bohle, W. Seeger, F. Rose, L. Fink, A. Guenther, O. Eickelberg (Giessen, Germany)
|  |
RhoA signalling influences cyclin D1 expression and associated fibroblast turnover: implications for idiopathic pulmonary fibrosis (IPF)
K. L. Watts, E. Cottrell, P. R. Hoban, M. A. Spiteri (Stoke on Trent, United Kingdom)
|  |
Involvement of FHL1 in vascular remodelling
G. Kwapiszewska, R. Troesser, S. Schmitt, W. Staerk, W. Seeger, L. Fink, R. M. Bohle, N. Weissmann (Giessen, Germany)
| |
The interleukin 13 receptor system is altered in pulmonary arterial hypertension
M. Hecker, G. Kwapiszewska, A. Zakrzewicz, D. Sedding, W. Klepetko, W. Seeger, O. Eickelberg (Giessen, Germany)
| |
Shroom expression is attenuated in hypoxia-induced pulmonary hypertension
J. Sevilla-Perez, G. Kwapiszewska, W. Seeger, O. Eickelberg (Giessen, Germany)
| |
Dysregulation of TGF-β/BMP signaling in a monocrotaline model of pulmonary hypertension
R. E. Morty, B. Nejman, F. Kouri, A. Zakrzewicz, M. Hecker, R. Sandu, R. Dumitrascu, R. T. Schermuly, W. Seeger, O. Eickelberg (Giessen, Germany)
| |
A BTNL2 gene variant confers to sarcoidosis susceptibility by an increased risk towards the chronic form of the disease
S. Pabst, Y. Li, B. Wollnik, M. Lennarz, E. Rohmann, A. Gillissen, H. Vetter, C. Grohe (Bonn, Cologne, Leipzig, Germany)
| |
Toll-like receptor (TLR) 2 promotor polymorphism is associated with the disease course in sarcoidosis patients
M. Veltkamp, J. C. Grutters, C. H. M. van Moorsel, H. J. T. Ruven, J. M. M. van den Bosch (Nieuwegein, Netherlands)
| |